Product image of Inegy (Simvastatin, Ezetimibe) supplied by GNH India

Inegy

Active Ingredient:
Simvastatin, Ezetimibe
Origin:
EU

Inegy (Simvastatin, Ezetimibe)

Simvastatin, the active ingredient in Inegy, is a HMG‑CoA reductase inhibitor presented as a fixed‑dose combination tablet for oral use. It works together with ezetimibe to lower low‑density lipoprotein cholesterol and total cholesterol, addressing hypercholesterolemia, mixed dyslipidemia, and primary hyperlipidemia in adult patients.

GNH India supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global distribution. The company adheres to stringent quality standards and offers comprehensive logistics solutions to meet the needs of healthcare providers across multiple regions.

Manufacturer / TM Owner

Organonhealthcare Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Inegy combines simvastatin and ezetimibe to lower cholesterol by targeting both synthesis and absorption pathways, and is indicated for the following lipid disorders:
  • Hypercholesterolemia: reduces low‑density lipoprotein cholesterol and total cholesterol, helping achieve target lipid levels in adults with elevated cholesterol.
  • Mixed dyslipidemia: improves the overall lipid profile, including reductions in LDL‑C, total cholesterol, and triglycerides, for patients with combined lipid abnormalities.
  • Primary hyperlipidemia: lowers elevated cholesterol concentrations in patients with familial or genetic lipid disorders, supporting long‑term cardiovascular risk management.

How It Works

  • Simvastatin inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, thereby decreasing intracellular cholesterol and up‑regulating LDL receptors. Ezetimibe blocks the NPC1L1 transporter on enterocytes, reducing intestinal absorption of dietary and biliary cholesterol. The combined effect results in a synergistic reduction of circulating LDL‑C and total cholesterol levels.

Side Effects

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Muscle aches or weakness
  • Elevated liver enzymes (ALT, AST)
  • Gastrointestinal discomfort such as nausea or diarrhea
  • Headache
  • Dizziness
  • Fatigue

Serious or Rare Side Effects

  • Rhabdomyolysis leading to renal impairment
  • Severe hepatic injury or hepatitis
  • Acute allergic reactions including rash and angioedema
  • Myopathy with marked CK elevation
  • Pancreatitis

Precautions & Warnings

  • Before initiating therapy with Inegy, consider the following safety measures:
  • Liver function monitoring: obtain baseline and periodic ALT/AST levels.
  • Muscle symptom vigilance: advise patients to report unexplained muscle pain or weakness.
  • Drug interaction awareness: avoid concomitant use of strong CYP3A4 inhibitors.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
  • Renal impairment: adjust therapy based on renal function and monitor for accumulation.
  • Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Inegy can interact with several medications; careful assessment is required.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)
  • Gemfibrozil
  • Cyclosporine
  • High‑dose niacin
  • Certain HIV protease inhibitors

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium
  • Warfarin (may increase INR)
  • Digoxin (potential increased serum levels)
  • Beta‑blockers (enhanced lipid‑lowering effect)
  • Fibrates (monitor for muscle toxicity)

Frequently Asked Questions

Inegy is a prescription medication that combines simvastatin and ezetimibe to lower elevated cholesterol levels. It is indicated for adults with hypercholesterolemia, mixed dyslipidemia, or primary hyperlipidemia, helping reduce low‑density lipoprotein cholesterol and total cholesterol to meet therapeutic targets.

Simvastatin, one of the active ingredients in Inegy, inhibits the enzyme HMG‑CoA reductase in the liver, which is essential for cholesterol synthesis. By reducing hepatic cholesterol production, it increases the number of LDL receptors on liver cells, enhancing clearance of LDL‑C from the bloodstream.

The dosage of Inegy is individualized by a qualified prescriber based on the patient’s lipid profile, treatment goals, and overall health status. Only a healthcare professional can determine the appropriate strength and dosing regimen for each patient.

Safety data for Inegy in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To request Inegy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Inegy offers a dual mechanism by combining a statin (simvastatin) that reduces cholesterol synthesis with ezetimibe, which blocks intestinal absorption. This can provide greater LDL‑C reduction than a statin alone and may be an alternative to higher‑dose statin therapy or other combination products.

Inegy tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, heat, and direct sunlight to maintain product stability and potency.

Inegy is taken orally, usually once daily, with or without food, as directed by a prescriber. Swallow the tablet whole with a glass of water and follow any specific instructions provided by the healthcare professional.

The most serious adverse reactions to monitor include rhabdomyolysis, severe liver injury, and allergic reactions such as rash or angioedema. Patients should promptly report unexplained muscle pain, weakness, dark urine, jaundice, or signs of an allergic response.

Inegy is contraindicated in patients with active liver disease, unexplained persistent elevations of hepatic enzymes, known hypersensitivity to simvastatin, ezetimibe, or any excipients, and in individuals taking strong CYP3A4 inhibitors that cannot be discontinued.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Simvastatin, Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT